Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mononuclear cells (Royan Institute)
- Development stage
- Unknown
- Lead developer
- Royan Institute for Stem Cell Biology and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
This autologous cell therapy is being developed by the Royan Institute for Stem Cell Biology and Technology for the treatment of critical limb ischemia (CLI) and advanced chronic lower limb ischemia. The treatment involves the extraction of mononuclear cells from the patient's own bone marrow (BM-MNCs), which are then processed and injected directly into the affected ischemic limb. The therapeutic approach relies on regenerative medicine and therapeutic angiogenesis; the transplanted cells are thought to secrete various pro-angiogenic growth factors and cytokines that stimulate the formation of new blood vessels and improve blood perfusion in oxygen-deprived tissues. Clinical studies, including Phase 1/2 trials, have evaluated the safety and efficacy of these cell injections, sometimes in conjunction with granulocyte colony-stimulating factor (G-CSF) to enhance the mobilization or therapeutic potential of the cells.
- Other names
- autologous bone marrow mononuclear cell transplantationBM-MNCsbone marrow-derived mononuclear cells
Beyond the preview
Go deeper on autologous bone marrow-derived mononuclear cells (Royan Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mononuclear cells (Royan Institute).